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Abstract: Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin 
therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as 
clinicians strive to help their patients reach glycemic goals. Basal insulins have been continually 
improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, 
have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hage-
dorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a 
longer duration of action. Overall, glargine and detemir do not differ greatly in their safety and 
efficacy profiles. Major differences between the two include lower within-subject variability, 
lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir. This review sum-
marizes data from the key pharmacokinetic and pharmacodynamic studies, as well as clinical 
and observational studies to elucidate the role of each basal insulin analog in therapy.
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Introduction
Diabetes mellitus is a common, chronic illness. In the year 2000, the number of cases of 
diabetes in the US was 17.7 million.1 Worldwide, that number is at least 171 million.2 The 
number of people with diabetes continues to grow in epidemic proportions. The world-
wide prevalence of diabetes is projected to increase to 366 million in 2030.1 Along with 
the prevalence of the disease, the global burden of diabetes continues to grow. Although 
the incidence of type 2 diabetes is increasing at younger ages, most of the people with 
diabetes in developed countries are older adults.2 However, in developing countries, 
diabetes affects mostly people aged 35–64 years.2 This has serious implications in terms 
of the costs of loss in productivity. Due to its chronic nature, diabetes is a costly disease 
for the individual, health care systems, and society. Complications of diabetes cause 
3.2 million deaths per year, and 2.5%–15% of annual health care budgets are used for 
diabetes-related care.2 As we rise to meet the challenges of the diabetes epidemic, preven-
tion of complications through glycemic control in persons with diabetes is the goal, and 
safe and efficacious treatment will play a role in achieving that goal. This review focuses 
on insulin therapy, specifically on the safety and efficacy profiles of the long-acting basal 
insulin analogs, glargine and detemir, and the place of each in therapy.
Glycemic control in patients with diabetes
The underlying pathophysiology of diabetes mellitus is absolute or relative insu-
linopenia and, in the case of type 2 diabetes, there is insulin resistance as well. 
Large-scale landmark studies have demonstrated the benefits of insulin therapy.3–7 Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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The Diabetes Control and Complications Trial (DCCT) 
showed that in type 1 diabetes mellitus, compared with 
conventional daily or twice-daily insulin therapy, intensive 
insulin therapy (at least three daily insulin injections or pump 
treatment) resulted in a significant decrease in microvascular 
complications, and any improvement in HbA1c resulted in 
a decreased risk of complications.3 The follow-up observa-
tional Epidemiology of Diabetes Interventions and Compli-
cation (EDIC) study that was an extension of the DCCT also 
found that physiologic insulin replacement therapy decreased 
macrovascular risks in type 1 patients with diabetes mellitus 
and that the macrovascular benefits persisted from earlier 
physiologic insulin treatment, even when treatment was later 
equalized (a phenomenon known as “metabolic memory”).4 
Benefits of insulin treatment are not limited to people with 
type 1 diabetes mellitus. The Kumamoto Study paralleled 
the DCCT and found a decreased incidence of microvascular 
complications (retinopathy and nephropathy) in insulin-
requiring type 2 diabetes   mellitus patients.5 The United 
Kingdom Prospective Diabetes Study (UKPDS) followed 
type 2 diabetes mellitus patients over 10 years and found that 
the intensive treatment group (sulfonylurea + insulin) fared 
better than the conventional group in regards to decreased 
microvascular disease.6 In a 10-year post-trial follow-up of 
the UKPDS, there was a “legacy effect” of earlier glucose 
control, ie, a decrease in any diabetes-related endpoint, 
decreased microvascular disease, decreased myocardial 
infarction, and decreased all-cause mortality.7
The American Diabetes Association and the European 
Association for the Study of Diabetes, as well as the 
American Association of Clinical Endocrinologists/Ameri-
can College of Endocrinology have released statements on 
glycemic goals (see Table 1).8–10 Although the glycosylated 
hemoglobin (HbA1c) goals differ, both guidelines advocate 
the early use of insulin. Insulin therapy is an effective 
means for achieving glycemic control and, as such, plays 
an important role in treatment.
Long-acting basal insulin analogs
Insulin exerts its actions through binding to the insulin 
receptor. It regulates glucose metabolism by promoting 
the synthesis and storage of glycogen, triglycerides, and 
protein in its major target tissues, ie, liver, fat, and muscle, 
and it inhibits hepatic glucose production. Long-acting basal 
insulin analogs (glargine and detemir) are the initial choice 
of insulin treatment in the US, and they are preferred over 
neutral protamine Hagedorn (NPH) insulin because of a 
longer duration of action,11 less pronounced peak in time-
action profiles,12 more consistent effects (less variability),12 
and decreased risk of hypoglycemia.12 Glargine and detemir 
are the two long-acting basal insulin analogs currently avail-
able on the market.
Molecular structures  
of glargine and detemir
Basal insulin analogs were created to improve on the short-
comings of NPH (ie, pronounced peak, short duration of 
action, variable absorption rates) and to mimic better the 
normal physiologic basal insulin response.
Insulin glargine (GlyA21 ArgB21 ArgB32 human insulin) 
is synthesized via recombinant DNA technology using 
Escherichia coli K12.13 The amino acid asparagine at posi-
tion A21 in human insulin is replaced with glycine, and 
two arginines are added to the C-terminus of the β-chain 
(Figure 1a).13 These modifications cause a shift in the 
isoelectric point towards neutrality. At a pH of 4 in acidic 
solution, glargine is not soluble at physiologic neutral pH 
and forms a microprecipitate upon injection into subcuta-
neous tissue.13
Insulin detemir [LysB29 (N-tetradecanoyl)des(B30)human 
insulin] is also synthesized via recombinant technology, 
using the yeast Saccharomyces cerevisiae.14 It differs from 
human insulin in that the amino acid threonine in position 
B30 is omitted and a carbon 14 fatty acid chain is attached 
to lysine at B29 (Figure 1b).14 Detemir has a pH of 7.4 and 
is therefore soluble at physiologic pH.14 It is reversibly 
bound to albumin.14 Both glargine and detemir are clear 
solutions13,14 that unlike NPH do not require resuspension 
prior to injection.
Pharmacokinetics
Pharmacokinetics govern drug absorption, distribution, and 
elimination. The pharmacokinetic goals for basal insulin 
analogs are a steady rate of absorption, avoidance of peaks 
in plasma levels, and a predictable absorption profile.15
Glargine achieves a slower, more prolonged absorption 
profile through reduced solubility at physiologic pH.16 Upon 
injection into neutral pH subcutaneous tissue, glargine 
forms microprecipitates that dissolve slowly, delaying its 
absorption and thus prolonging its duration of action.16 
Table 1 Glycemic goals
American Diabetes Association and the  
european Association for the Study of Diabetes 
HbA1c , 7.0%
American Association of Clinical endocrinologists/
American College of endocrinology
HbA1c # 6.5%Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Owens et al17 investigated the subcutaneous absorption 
rates of radioactively-labeled insulin glargine of differing 
zinc contents (15, 30, and 80 µg/mL), in comparison with 
NPH, by measuring the rates of disappearance of radio-
activity. Glargine was absorbed more slowly and with a 
relatively peakless profile versus NPH, which demonstrated 
a pronounced peak of action.17 Compared with each other, 
solutions of glargine with higher zinc content demonstrated 
a slower absorption profile, which is consistent with the 
role of zinc in glargine absorption.17 In a second study, they 
also found no significant difference in absorption rates of 
glargine with 30 µg/mL zinc content (formulation used in 
Phase II and Phase III clinical trials) when injected in dif-
ferent subcutaneous injection sites (arm, leg, abdomen).17 
The formulation of glargine that is currently on the market 
contains 30 µg/mL zinc.13
In comparison with glargine, detemir retains solubility at 
physiologic pH, and injection into the subcutaneous tissue 
forms a soluble depot.18 The acylation of detemir allows for 
reversible albumin binding, and along with its hexamer-
forming abilities (stabilizing self-association), results in 
prolonged action.18
Havelund et al19 investigated the underlying mechanism 
for the low variability in absorption of insulin detemir. Using 
size-exclusion chromatography and manipulation of the 
contents of the eluent to simulate changes at the injection 
depot, they modeled self-association and albumin affinity 
of detemir and other insulin analogs in pigs at the injec-
tion depot, the depot-interstitial junction, and in plasma. 
The data suggest that one mechanism by which absorption 
of detemir after subcutaneous injection is protracted is 
via self-association into dihexamers, presumably through 
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interactions between the fatty acid chains.19 Hexameric 
detemir reaches a hexamer–dihexamer equilibrium after 
injection in subcutaneous tissue, because preservatives such 
as phenol, cresol, and polyol in the pharmaceutical formula-
tion diffuse across the endothelial membranes and sodium 
chloride enters the subcutaneous injection depot.19 At the 
depot–interstitial junction, detemir comes into contact with 
and binds to albumin; all forms of insulin detemir (mono-
meric, hexameric, and dihexameric) will bind to albumin.19 
In comparison with the acylated insulin analogs, those with 
more stable self-association states have slower disappearance 
rates (T1/2), ie, 10.2 hours for detemir versus 8.8 hours for 
acylated stable hexamer, 6.9 hours for an acylated weakly 
associating hexamer, and 2.9 hours for an acylated mono-
mer.19 This suggests that self-association is an important 
property in the absorption rate of detemir. However, the 
stable nonalbumin-binding hexamer Co (III) insulin had an 
elimination half-life of only 2.8 hours. This suggests that 
not only does the extent of self-association influence the 
absorption rate of the insulin analog, but albumin binding 
also appears to play a role in delaying absorption. The pro-
posed mechanism of action is that self-association of detemir 
increases retention in the injection depot, slowing absorption 
and increasing albumin-binding opportunities, and albumin 
binding in the depot further delays absorption.
In a compartmental (plasma and interstitial fluid) 
modeling study, Dea et al20 infused equimolar amounts of 
an acylated insulin analog NN304 [LysB29 (tetradecanoyl) 
des (B30) human insulin] or human insulin in dogs under 
euglycemic clamp conditions to determine how albumin 
binding affected NN304 action, ie, whether it was due 
only to its unbound (and presumably active) fraction. Dea 
et al20 found that elimination and transendothelial transport 
of NN302 to interstitial fluid was reduced, compared with 
human insulin, although not to the degree expected for 
an albumin-binding insulin analog. However, there was 
no reduction in action (glucose uptake) of NN304 versus 
human insulin once it was in the interstitial fluid, despite 
high concentrations of albumin and predicted albumin 
binding.20 This suggests that the albumin-binding property 
of NN304 blunts plasma kinetics (hepatic elimination and 
transendothelial transport), as compared with human insu-
lin, thus delaying entrance into the interstitial fluid, but it 
does not blunt the kinetics or efficacy in interstitial fluid 
which is the compartment of action.
Albumin binding may also have buffering effects against 
variable absorption. Because detemir is 98% albumin-bound 
in the circulation, variations in blood flow rate at the injection 
site do not affect absorption rates to as great an extent.18 
Absorption normally depends on movement across capillary 
membranes governed by a concentration gradient and on the 
capillary flow rate. A high flow rate will decrease capillary 
concentration and increase absorption from the interstitium, 
while a low flow rate will increase capillary concentration 
and decrease absorption of insulin from the interstitial fluid.18 
Insulin detemir is almost completely albumin-bound once 
it is injected into the subcutaneous tissue, and albumin-
bound detemir forms rather large complexes that do not 
easily traverse capillary membranes.18 Therefore, the free 
detemir concentration is relatively constant and indepen-
dent of flow rate, which may explain decreased variability 
in absorption.
Pharmacodynamics
Pharmacodynamics relate to the pharmacologic effect of a 
drug, ie, the clinical response. The pharmacodynamic goals 
of basal insulin analogs are protracted action15 and potency 
(dose-response). Isoglycemic clamp studies are considered 
the gold standard for pharmacodynamic research.21 However, 
the methodology of glucose clamp studies may vary consider-
ably, making comparisons between studies difficult.
Insulin glargine has a relatively constant concentration/
time action profile and long duration of action. According 
to the manufacturer’s package insert13 for Lantus® (sanofi-
aventis, Paris, France), the median duration of action was 
24 hours with a range of 10.8 to .24 hours.
In a double-blind, randomized, two-way crossover, eug-
lycemic clamp study22 comparing the time-action profiles 
of HOE 901 (insulin glargine) and NPH in subjects with 
type 1 diabetes, the onset of action was slower with glargine 
(1.11 hours versus 0.71 hours), but the median duration 
of action of glargine was significantly longer than NPH 
(22.8 hours versus 13.8 hours). Glargine was also found to 
have a flatter, consistent glucose infusion rate (GIR)-time 
profile compared with NPH.22
Heinemann et al16 also conducted a randomized, double-
blind, placebo-controlled, three-way, crossover euglycemic 
glucose clamp study to determine the pharmacodynamic 
properties of injecting 0.4 U/kg body weight insulin glargine 
compared with 0.4 U/kg NPH. The metabolic activity of 
glargine reached a plateau within four hours after subcutane-
ous injection, whereas NPH showed a peak at 4–6 hours.16 
With time, metabolic activity declined with both insulins, 
but the duration of action of glargine was at least 30 hours in 
this study. However, this was a single-injection study, and 
steady state was not established.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Porcellati et al23 conducted a randomized, double-blind, 
crossover euglycemic glucose clamp study comparing the 
pharmacokinetics and pharmacodynamics of glargine and 
detemir at steady state in type 1 diabetes patients. They 
used a dose of 0.35 U/kg body weight for both glargine and 
detemir, and found a decreased GIR and GIR area under the 
curve with detemir after 12 hours, but not with glargine, 
and decreased lipolytic activity of detemir compared with 
glargine. Based on their findings, Porcellati et al suggested 
that glargine be used as a once-daily basal insulin for people 
with type 1 diabetes, while detemir requires twice-daily use. 
These results differ from other glucose clamp studies (albeit 
of different designs) that have demonstrated a similar duration 
of action for glargine and detemir.
Heise et al12 conducted a randomized, double-blind 
euglycemic glucose clamp study to compare within-subject 
variability in the glucose-lowering effect of detemir, NPH, 
and glargine in type 1 diabetes. In comparison with the 
Porcellati study, Heise et al12 used a larger dose of detemir 
(0.4 U/kg versus 0.35 U/kg), and they used the Biostator 
instead of the manual clamp technique. In this study, they 
demonstrated a more predictable glucose-lowering effect 
with detemir. Within-subject variability for GIR area under 
the curve (0–12 hours) and over 24 hours was lower for 
detemir versus both NPH and glargine. Also, within-subject 
variability was lower for detemir. The authors hypothesized 
that the differences in variability seen with detemir versus 
NPH and glargine may be due to their differing mechanisms 
of protraction after subcutaneous injection. Incomplete resus-
pension of NPH, and in the case of glargine, necessity for 
precipitation and dissolution in the subcutaneous tissue may 
be sources of variation. The duration of action of detemir in 
this study was a median of 23.0 hours (range 15.4–24 hours) 
and 24.0 hours (range 18.7–24 hours) for glargine.12
Plank et al24 also found a dose-dependent duration of 
action for insulin detemir in type 1 diabetes from 5.2 hours 
at the lowest dose of 0.1 U/kg to 23.2 hours at the highest 
dose of 1.6 U/kg and a flat and protracted pharmacodynamic 
profile (Figure 2). Limitations of this study include it being 
a first-dose study and not a steady-state study.
In people with type 2 diabetes, Klein et al25 compared the 
time action profiles of detemir, NN304 (another albumin-
bound basal analog), and glargine. They found that the 
duration of action was dose-dependent with both glargine 
and detemir. At low and medium doses (0.4 U/kg, 0.8 U/kg), 
the duration of action was below 24 hours. Because the 
duration of action of glargine and detemir were comparable 
in this study, the authors asserted that insulin detemir is just 
as appropriate for once-daily dosing as insulin glargine in 
type 2 diabetes patients. Within-subject variability was lower 
with detemir versus glargine and there was no significant 
difference in between-subject variability. No major differ-
ences were found in shape of metabolic profiles (GIR) and 
duration of action or effect on endogenous glucose produc-
tion, peripheral glucose uptake, and free fatty acids between 
detemir and glargine (at doses of 0.4–0.8 U/kg). None of the 
three insulins tested showed a peakless profile, with equal 
distribution of metabolic effect over 24 hours.
In an attempt to consolidate the information from the 
different isoglycemic clamp studies comparing glargine 
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and detemir, Heise and Pieber21 reviewed the areas of major 
contention, including the mean shape of their pharmacody-
namic profile (ie, “flatness” of action, as measured by the 
shape of their GIR curves), duration of action, and variabil-
ity of the two insulins. They reviewed 10 studies (five with 
subjects having type 1 diabetes, two with type 2 diabetes 
subjects, and three with healthy subjects) and found that 
results of the studies were fairly consistent, despite method-
ologic differences. Both detemir and glargine exhibit overall 
flatter pharmacodynamic profiles than NPH, but a small peak 
occurs for both in the form of a “gentle rise and fall” in effect 
over 24 hours.21 The duration of action (close to 24 hours) was 
found to be similar between glargine and detemir at clinically 
relevant doses of 0.35–0.8 U/kg.21 The Porcellati et al study23 
is the exception to this. In regards to variability, detemir dem-
onstrates less within-subject variability in its effect. Neither 
insulin glargine nor insulin detemir perfectly mimics the 
physiologic, peakless profile of endogenous basal insulin.
Comparison of effectiveness  
in glycemic control
It is fairly well established that glargine and detemir have 
improved pharmacokinetic and pharmacodynamic profiles, 
as compared with NPH. This raises the questions of how 
do these two basal insulin analogs compare with NPH and 
with each other in terms of glycemic control? Many studies 
have compared glargine and detemir with NPH, but few 
studies have compared glargine and detemir head-to-head. 
This review focuses mainly on studies that compare glargine 
with detemir.
Clinical trials with NPH
Horvath et al26 conducted a meta-analysis comparing the 
efficacy of glargine and detemir with that of NPH in patients 
with type 2 diabetes. Glargine and detemir were almost iden-
tically effective, compared with NPH, in long-term metabolic 
control (as measured by HbA1c). There was no significant 
difference for severe hypoglycemia rates in any of the tri-
als, but the rates of symptomatic hypoglycemia were lower 
with glargine, overall hypoglycemia was lower with detemir, 
and nocturnal hypoglycemia was lower with glargine and 
detemir, versus NPH. No evidence was obtained on the 
beneficial effect of glargine and detemir on patient-oriented 
outcomes, ie, mortality, morbidity, quality of life, or costs. 
Therefore, the authors could only conclude that there was a 
minor clinical benefit of long-acting insulin analogs for type 
2 diabetes patients treated with basal insulin in regards to 
nocturnal hypoglycemia. Although the results of this study 
were disappointing, it is important to keep in mind that the 
methodologic quality of the studies used was rated low.
Clinical trials with glargine and detemir
Pieber et al27 compared glycemic control and risk of hypogly-
cemia in patients with type 1 diabetes randomized to either 
twice-daily insulin detemir or once-daily insulin glargine 
injections, in combination with premeal aspart to demonstrate 
noninferiority. The HbA1c improvement was comparable in 
both groups, but the target of 7.0% was not reached in either 
study. Home-measured fasting blood glucose (BG) was lower 
with glargine. No significant difference was found between 
the overall within-subject variation in plasma glucose, but 
within-subject variation in pre-dinner plasma glucose was 
lower with detemir. This may be due to a waning effect of 
glargine (only once-daily injection allowed per US Food and 
Drug Administration guidelines) or a lower mean predinner 
BG for detemir (in some subjects, a morning detemir dose 
was added if predinner BG was not at goal). The difference 
in overall risk of hypoglycemia was not statistically signifi-
cant, but the risk of severe and nocturnal hypoglycemia was 
lower with detemir (higher plasma glucose in early morning 
was seen with detemir). There was no significant difference 
in weight gain. The mean daily basal dose was higher with 
detemir compared with glargine (0.47 versus 0.35 U/kg), 
but bolus insulin doses were lower in detemir group (0.36 
versus 0.39 U/kg). The total mean daily dose of insulin was 
0.83 U/kg with detemir versus 0.74 U/kg with glargine, 
attributable to twice-daily dosing of detemir. In light of these 
results, the authors concluded that twice-daily detemir dosing 
is as effective as once-daily glargine when used in combina-
tion with premeal aspart in type 1 diabetic patients. Detemir 
also has the advantage of reduced risk of severe and nocturnal 
hypoglycemia, compared with glargine.27
Rosenstock et al28 conducted a parallel-group, head-
to-head comparison of detemir (once or twice daily) to 
glargine (once daily) as add-on treatment to oral antidi-
abetic agents for type 2 diabetes patients. They were able 
to demonstrate noninferiority for detemir at higher doses 
(mainly twice-daily dosing). The mean daily detemir dose 
was higher, ie, 0.78 U/kg (0.52 U/kg with once-daily dos-
ing, 1.00 U/kg with twice-daily dosing) than the mean 
daily dose of glargine (0.44 U/kg). Less weight gain 
occurred with once-daily detemir (3.0 kg) versus glargine 
(3.9 kg). Within-participant variability for self-monitored 
fasting BG and predinner plasma glucose did not differ 
by treatment nor did relative risk of overall nocturnal 
hypoglycemia.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Hollander et al29 compared once- or twice-daily insulin 
detemir with once-daily glargine in a basal–bolus regimen for 
type 2 diabetes patients. They found no difference between 
glargine and detemir in regards to mean HbA1c or decrease in 
HbA1c or in mean fasting BG or mean decrease in fasting BG 
from baseline. Interestingly, the decrease in HbA1c was not 
significantly affected by whether detemir was administered as 
a once a day or twice a day injection, suggesting that adding a 
second dose of basal insulin for predinner BG may not offer 
a clinical advantage over once-daily dosing in type 2 diabetes 
patients.29 The doses of basal and prandial insulins were not 
significantly different between the two groups. There was 
also no significant difference between glargine and detemir 
in regards to hypoglycemia and adverse effects. Of note is 
that mean weight gain was lower with the detemir group, ie, 
2.8 kg versus 3.8 kg in the glargine group.
Many clinical trials have used twice-daily detemir dos-
ing in comparison with once-daily glargine, which makes 
comparison of the two basal insulins difficult. In a random-
ized, double-blind, crossover study using continuous glucose 
monitoring, King30 demonstrated that administration of once-
daily detemir in type 2 diabetes patients was equally effective 
in achieving glucose goals as once-daily glargine. The mean 
dosage used for the two basal insulins were not significantly 
different, with a mean dosage of 0.26 U/kg.
The PREDICTIVE trials were multinational, prospec-
tive, observational studies examining the safety and efficacy 
of detemir in diabetic patients in real-life clinical practice. 
Those trials were uncontrolled and unblinded, but large-
scale. In these studies, insulin detemir was found to improve 
glycemic control (as measured by HbA1c) in both type 1 and 
type 2 diabetic patients, while causing less hypoglycemia and 
less weight gain (weight neutral).31 In other PREDICTIVE 
studies,32–34 type 2 diabetes patients treated with basal insulin 
in combination with oral antidiabetic drugs who switched 
to detemir from NPH or glargine achieved a mean HbA1C 
reduction of up to 0.6%, reductions in total and nocturnal 
hypoglycemia, and also weight loss.
Short and long-term safety  
and tolerability profiles
Hypoglycemia
Hypoglycemia is a major barrier and limiting factor in the 
glycemic management of patients with diabetes. Because 
of it, the goal of euglycemia remains elusive. Under normal 
physiologic conditions, the body has evolved mechanisms 
that prevent wide fluctuations in glucose levels. Hypogly-
cemia is an iatrogenic clinical event that occurs in people 
who use drugs, such as insulin and insulin secretogues, that 
raises circulating exogenous or endogenous insulin levels 
and lowers the plasma glucose concentration.35 In individu-
als with type 1 diabetes, hypoglycemia is quite common, 
in that blood glucose levels may be below 2.8 mmol/L 
(,50 mg/dL) up to 10% of the time and, on average, a patient 
will experience two symptomatic hypoglycemic episodes 
per week and one episode per year of severe temporarily 
incapacitating hypoglycemia that may include seizure or 
coma.35 Although hypoglycemia is less frequent in people 
with type 2 diabetes, it becomes more of a factor later in 
the course of the disease with progressive beta cell failure, 
and increases with duration of insulin therapy until the risk 
approaches that in type 1 diabetes.35 The impact of hypo-
glycemia in terms of morbidity include unpleasant physical 
symptoms, potential cognitive impairment in children, and 
fear and anxiety over hypoglycemia itself, and a mechanism 
of mortality may be cardiac arrhythmia.35 Because patients 
are more likely to remember severe hypoglycemic episodes, 
and because severe hypoglycemic episodes by nature pose a 
greater risk, estimates of the incidence of those episodes 
are the most reliable, although they only represent a small 
number of total hypoglycemic episodes.35 When data on 
hypoglycemia incidence are obtained from clinical trials, one 
has to take into account that most of the time, hypoglycemia 
is not a primary outcome and the manner in which the data 
were collected varies, with prospective data collection being 
more reliable than that from retrospective studies.35
In a treat-to-target trial, Riddle et al36 randomized type 2 
diabetic subjects who were already on oral therapy to either 
glargine or NPH for further glycemic control to an HbA1c goal 
of ,7.0%. Hypoglycemia was one of the primary outcome 
measures. At the end of the study, mean fasting BG values 
and HbA1c were comparable between the two groups, but 
the rates of nocturnal hypoglycemia and other symptomatic 
hypoglycemia was lower with glargine. So, compared with 
NPH, the addition of glargine to oral diabetic medications 
can help type 2 diabetics achieve an HbA1c goal of ,7.0%, 
without increased risk of hypoglycemia.
The Pieber et al study27 and the PREDICTIVE® studies31–34 
demonstrated less hypoglycemia with detemir compared with 
both glargine and NPH.
Hypoglycemia and fear of hypoglycemia may affect 
adherence to treatment and be a barrier to euglycemia. 
Because of their pharmacokinetic and pharmacodynamic 
profiles, basal insulin analogs, glargine and especially 
detemir, are less likely than NPH to cause hypoglycemia. 
This allows for insulin doses to be titrated upward closer to Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
220
Poon and King
goal without increased hypoglycemia and its accompanying 
morbidity and mortality.
Allergic and injection site reactions
Rosenstock et al28 found more frequent injection site reac-
tions with detemir compared with glargine (4.5% versus 
1.4%, respectively). There was a higher withdrawal rate 
of subjects in the detemir group (21% versus 13%), partly 
due to adverse effects (8% versus 4%) such as injection 
site reactions.
Drug–drug interactions
The reversible albumin-binding properties of detemir raise 
the concern of potential competitive albumin binding of other 
compounds in the serum. This risk is minimized, because the 
molar serum concentration of insulin detemir is 1:50,000 of 
albumin at therapeutic doses.18 That and the numerous fatty 
acid binding sites (eight sites) on each albumin molecule 
make it unlikely that detemir will occupy binding sites to 
a significant extent.18 In vitro studies have shown that even 
at a detemir:albumin concentration of 1:1, detemir did not 
interact or interfere with drugs such as phenylbutazone, 
warfarin, ibuprofen, diazepam, tolbutamide, glibenclamide, 
aspirin, or valproate.18
Mitogenicity potential of insulin analogs
Novel insulin analogs provide many benefits of improved 
glycemic control, but these benefits must not be achieved 
at the cost of increased safety risks for long-term users. 
In the early stages of insulin analog development, it was 
found that a single substitution in the amino acid sequence 
of the insulin molecule into B10 Aspart led to increased 
mitogenic activity in rodents.37 The mechanism behind the 
increased mitogenic activity is not clear, but B10 Aspart 
had an increased insulin-like growth factor 1 receptor to 
insulin receptor affinity ratio and an increased receptor 
binding time.37 The lesson learned from B10 Aspart is that 
it is important to test fully the toxicopharmacologic effects 
of insulin analogs.
The safety profile of the basal insulin analogs at the 
receptor/cell level was determined using measurements of 
receptor affinities by Kurtzhals et al.37 The insulin receptor 
(IR) affinity of glargine is similar to that of human insulin, 
while detemir has a lower IR affinity. Human insulin receptor 
(h-IR) binding and human insulin-like growth factor receptor 
(hIGF-IR) binding of detemir was less potent than human 
insulin, with hIGF-IR binding even less potent than that of 
h-IR binding, and the IR residence time was not increased.37 
Insulin detemir did not exhibit an increased mitogenic 
potency.37 Insulin glargine had a 6.5 time greater potency in 
binding to the IGF-I receptor and greater mitogenic potency 
than human insulin, due to the B31B32diArg substitution 
which provides glargine with a greater affinity for the IGF-I 
receptor.37 But the receptor residence time of glargine was 
not different from that of human insulin. These findings are 
greater than previously reported. The clinical safety implica-
tions of these findings are not clear, but in comparison with 
glargine, insulin detemir, because of its lower hIGF-R bind-
ing potency and lower mitogenic potency, does not appear 
to cause safety concerns.
A recent German observational, retrospective study pub-
lished by Hemkins et al raised the concern of an increased risk 
of malignancies with human insulin and glargine.38 However, 
this study is fraught with methodologic shortcomings and 
limitations.38 For example, given the short exposure time 
to insulin glargine (1.31 years), it is unlikely that glargine 
caused cancer in the patients studied, and the observational 
groups lacked important controls.38 Ehninger and Schmidt39 
argued in their commentary on the Hemkins et al study that 
the observational data leading to the suggestion of increased 
risk of malignancies with insulin glargine are not founded on 
methodologically and statistically sound analyses, and that 
more sound scientific evidence is needed before conclusions 
such as those are made.
A consensus statement released by experts from the 
American Diabetes Association and the American Cancer 
Society40 addressed the increased risk of certain types of 
malignancies of the liver, pancreas, endometrium, and, to a 
lesser extent, the colon and rectum, breast, and bladder, in 
people with diabetes. The report acknowledged that although 
persons with diabetes who use exogenous insulin appeared 
to be at increased risk, the data on possible associations of 
insulin analogs to cancer (and glargine as compared with 
other analogs) are limited and inconclusive.
Pregnancy
Both glargine and detemir are rated by the Food and Drug 
Administration as Pregnancy category C drugs. Detemir has 
not been studied in pregnancy. Recently, Pollex et al41 stud-
ied the use of glargine during pregnancy in a transplacental 
ex vivo human placental lobule perfusion study. Their results 
suggest that at therapeutic levels (150 pmol/L = 20 µU/mL, 
which is the therapeutic level achieved after subcutaneous 
injection of a single dose of 0.3 U/kg), insulin glargine does 
not cross the placenta in measurable amounts.41 It also appears 
that the placenta may be able to sequester or metabolize very Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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high concentrations of insulin glargine.41 At this time, neither 
glargine nor detemir are approved for use in pregnancy. More 
studies are needed to investigate the safety of basal insulin 
analogs in pregnancy.
Special populations
Children and adolescents
Danne et al42 compared pharmacokinetic profiles of insulin 
detemir and NPH across and within different age cohorts, ie, 
in children and adolescents with type 1 diabetes and using 
adults as the reference group. They found no significant 
difference in the area under the curve and maximal serum 
concentrations of insulin detemir across age groups, and also 
decreased variability between subjects across and within 
each age group with detemir versus NPH. In regards to 
safety, no serious adverse events were reported and no major 
hypoglycemic episodes were recorded with detemir, and the 
frequency of minor hypoglycemia was similar to NPH and 
greater in children in general with both insulins. NPH showed 
a progressively more rapid absorption with an earlier peak 
in the younger age groups (children and adolescents), that 
was not seen with detemir, which increases free insulin levels 
and thus the risk of hypoglycemia.42 This study suggests that 
detemir is an appropriate basal insulin for use in children 
and adolescents with the added advantage of less pharma-
cokinetic variability over NPH, which may help reduce risk 
of hypoglycemia, and doses may be titrated similarly as is 
done with adults.
Older adults
With older adults, of main concern is decreased renal and/or 
hepatic function, which can result in decreased clearance/
elimination of insulin, leading to hypoglycemia. Higher area 
under the curve levels were seen with elderly patients using 
detemir.14 Cautious and conservative dosing is recommended 
for both glargine and detemir.
ethnic groups
Patient responses to different pharmaceutical agents may 
vary across ethnic groups. Hompesch et al43 evaluated the 
time-action profiles and dose-response relationships of 
insulin detemir and NPH in type 2 diabetics of different 
ethnic groups (African American, Hispanic/Latino, and 
Caucasian). There was a linear dose-response relationship 
for both detemir and NPH in all three groups. Therefore, 
similar dosing of detemir can be used in African Americans, 
Hispanics/Latinos, and Caucasians without the need for dif-
ferent titration algorithms.
Patient-focused perspectives
Apprehension about injections
Glargine and detemir are available in both vial and pen forms. 
sanofi-aventis produces the Opticlik© (reusable) and Lantus 
Solostar© (disposable) pens for delivery of glargine,13 and 
Novo Nordisk (Bagsværd, Denmark) produces the NovoPen© 
(reusable) and the FlexPen© (disposable) for the delivery of 
detemir.14 Because they are much more portable and easier 
to use, pens may help to increase patient acceptance, thereby 
improving satisfaction and adherence to treatment. One 
advantage over NPH is that both glargine and detemir are 
suitable for once-daily injection.13,14 Adherence to insulin 
regimens may increase as the complexity of those regimens 
decrease. Also, glargine and detemir do not require resuspen-
sion, providing greater consistency in insulin delivery.
weight gain
Weight gain is an undesirable effect of insulin therapy or 
intensification of insulin therapy. Potential weight gain can be 
a psychologic barrier to insulin initiation, and actual weight 
gain can affect tolerance and thus adherence and compliance 
with ongoing insulin treatment, leading to suboptimal glyce-
mic control. Insulin therapy is associated with a weight gain 
of 4.0–5.0 kg (8.8–11.0 lbs).44 This may be due to decreased 
glycosuria and overtreatment of hypoglycemia with increased 
caloric intake. Other possibilities include a role of insulin in 
lipogenesis and fat deposition and effects of insulin on central 
nervous system receptors that affect appetite.44 Weight gain 
is not only a cosmetic concern, but may also have an adverse 
effect on cardiovascular health, through worsening of blood 
pressure and lipid profiles.44
Hermansen and Davies45 reviewed the role of insulin 
detemir in reducing risk of insulin-associated weight gain. 
Weight gain in people with type 2 diabetes, who are usually 
already overweight or obese, leads to increased insulin resis-
tance and subsequent increased insulin needs.45 Insulin detemir 
is the only basal insulin shown consistently in randomized, con-
trolled clinical trials to have weight-sparing effects in patients 
with type 1 and type 2 diabetes.45 The weight-sparing effects of 
insulin detemir appear to be correlated with body mass index 
(BMI), with the patients having the greatest BMI experiencing 
the greatest reduction in weight.45 The physiologic basis for the 
weight-sparing effect of detemir is unknown. One hypothesis 
is that detemir’s predictable absorption and action reduce 
hypoglycemia and reactive overeating.45 Another hypothesis is 
that its albumin-binding properties give it a more physiologic 
profile in its effects on hepatic and peripheral tissues, to sup-
press endogenous glucose production and decrease lipogenesis, Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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respectively.45 Hennige et al46 found that insulin detemir has 
a tissue-selective action with a preference for the brain over 
peripheral tissues, likely due to its albumin-binding properties 
and fatty acid chain that allows it to cross the blood–brain bar-
rier more readily. Because insulin activity on IR receptors has 
an anorectic effect on mammalian brains under experimental 
conditions, this suggests a possible mechanism for the weight-
sparing effects of detemir.46
Conclusion
The improved pharmacokinetic and pharmacodynamic profiles 
of the basal insulin analogs, glargine and detemir, make them 
a better choice than NPH for basal insulin replacement. Com-
pared with each other, the ongoing debate is over which insulin 
has a flatter pharmacodynamic profile and longer duration of 
action. With the exception of one pharmacodynamic euglyce-
mic clamp study, most studies demonstrate a relatively peak-
less pharmacodynamic profile for both glargine and detemir 
and a comparable duration of action that is dose-dependent. 
Both glargine and detemir are equally effective and suitable for 
once-daily injection to achieve glycemic control. Safety and 
efficacy profiles are similar for both, with less hypoglycemia 
compared with NPH. Insulin glargine has a greater affinity 
for the human IGF-1 receptor and greater mitogenic potential, 
compared with human insulin and detemir, but further studies 
are needed to determine the clinical significance of this.
Patient perspectives that may influence the use of one basal 
insulin analog over the other include the weight-sparing effect, 
although modest, of detemir compared with NPH and glargine. 
Detemir also lasts 42 days once opened,14 compared with 28 days 
for glargine,13 so less insulin is wasted at smaller doses. In one 
study, injection site reactions were more common with detemir.
Glargine and detemir are promising basal insulin analogs, 
and both have a place in therapy. Provided that safety and 
efficacy profiles are equal between the two basal insulin 
analogs, selection of one over the other will most likely come 
down to patient-focused perspectives such as quality of life, 
patient satisfaction/acceptability, and adherence.
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